Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belnacasan - Vertex Pharmaceuticals

Drug Profile

Belnacasan - Vertex Pharmaceuticals

Alternative Names: UNII-00OLE78529; VX-765

Latest Information Update: 05 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer MedStar Health Research Institute; Vertex Pharmaceuticals
  • Class Aminobenzoic acids; Antipsoriatics; Dipeptides; Small molecules
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Discontinued Cardiovascular disorders; Cryopyrin-associated periodic syndromes; Epilepsy; Inflammation; Psoriasis

Most Recent Events

  • 14 Dec 2021 Phase-II clinical trials in COVID-2019 infections in USA (PO) (NCT05164120)
  • 30 Sep 2012 Discontinued - Phase-II for Cryopyrin-associated periodic syndromes (In adolescents, In the elderly, In adults) in United Kingdom (PO)
  • 31 Dec 2011 Vertex Pharmaceuticals initiates enrolment in a Phase-IIb trial for treatment-resistant epilepsy in USA (NCT01501383)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top